Affiliation:
1. Service d'Urologie, Université Paris Sud, Centre Hospitalier Bicêtre, France.
Abstract
In a double-blind, randomized, multicenter study, 463 adult women with symptomatic acute uncomplicated cystitis were treated orally with either a 400-mg single dose of rufloxacin (n = 226) or an 800-mg single dose of pefloxacin (n = 237). Escherichia coli (78%) and Proteus mirabilis (7%) were the most common isolates from 350 patients with significant pretreatment bacteriuria (uropathogens, > or = 10(5) CFU/ml). In the intention-to-treat analysis of patients with significant pretreatment bacteriuria, 343 patients were assessed for bacteriological outcome and 345 were assessed for clinical outcome. The bacteriological cure rate was 88% in the rufloxacin group and 84% in the pefloxacin group (95% confidence interval [CI] for difference in proportions, -4 to 12%), while the clinical resolution rate was 85 and 84%, respectively (95% CI, -8 to 9%). The per-protocol analysis demonstrated that among the 264 assessable patients, the bacteriological cure rate obtained with rufloxacin at 4 weeks of follow-up was comparable to that with pefloxacin (91 versus 85%; 95% CI, -3 to 15%). Among 295 clinically assessable patients, the clinical resolution rate at 4 weeks of follow-up was 89% in the rufloxacin group and 88% in the pefloxacin group (95% CI, -6 to 10%). Potentially drug-related adverse events occurred in 19% of the rufloxacin patients and in 18% of the pefloxacin patients. A single oral dose of 400 mg of rufloxacin is as effective and safe as a single oral dose of 800 mg of pefloxacin for the treatment of acute uncomplicated cystitis in women.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference39 articles.
1. Use of quinolones in treatment of prostatitis and lower urinary tract infections;Andriole V. T.;Eur. J. Clin. Microbiol. Infect. Dis.,1991
2. Balcabao I. P. M. T. Jiménez de Anta P. Salvà M. Martìn F. Marco J. Costa M. J. Giménez and L. Aguilar. 1993. Program Abstr. 6th Eur. Congr. Clin. Microbiol. Infect. Dis. abstr. 719.
3. Balcabao I. P. M. Martìn J. Costa M. J. Giménez P. Salvà and L. Aguilar. 1993. Program Abstr. 18th Int. Congr. Chemother. abstr. 543.
4. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans;Barre M.;J. Pharm. Sci.,1984
5. Incidence of multi-resistant gram-negative isolates in eight Dutch hospitals;Buirma R. J. A.;Scand. J. Infect. Dis. Suppl.,1991
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献